| Identification | Back Directory | [Name]
Dapiprazole | [CAS]
72822-12-9 | [Synonyms]
Dapitant
Dapiprazol
DAPIPRAZOLE
Dapiprazole HCl
3-(2-(4-(o-Tolyl)piperazin-1-yl)ethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
3-[2-[4-(2-Methylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridine
3-[2-[4-(2-Methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,5-a]pyridine
1,2,4-Triazolo[4,3-a]pyridine, 5,6,7,8-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- | [Molecular Formula]
C19H27N5 | [MDL Number]
MFCD00865637 | [MOL File]
72822-12-9.mol | [Molecular Weight]
325.45 |
| Hazard Information | Back Directory | [Uses]
Adrenergic (α-blocking); antiglaucoma agent; neuroleptic; psychotropic. | [Definition]
ChEBI: Dapiprazole is a N-arylpiperazine, a N-alkylpiperazine and a member of pyridines. It has a role as an alpha-adrenergic antagonist, a miotic, an ophthalmology drug and an antipsychotic agent. | [Brand name]
Rev-Eyes (Angelini). | [in vivo]
Dapiprazole hydrochloride (0-10 mg/kg or 0-3 mg/mice; i.p. or i.c.v.; once) reduces the overall severity of the opiate withdrawal symptoms in mice[1]. | Animal Model: | Swiss Albino male CD-1 mice weighing 20 -25 g, acute dependence model[1] | | Dosage: | 5, 7.5 and 10 mg/kg (i.p.) or 0.5, 1 and 3 mg/mice (i.c.v.), once | | Administration: | Intraperitoneal injection or intracerebroventricular administration, once | | Result: | Decreased jumping behavior, head shakes and paw shakes when administered just before naloxone. |
| [IC 50]
α1-adrenergic receptor |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|